BioSpace News Archive

IRLAB Therapeutics AB, a company discovering and developing novel treatments for Parkinson’s disease, announced that the company will hold a Capital Markets Day on October 17, 2023.

Crossject, a specialty pharma company developing needle-free autoinjectors for emergency situations, announces a significant improvement in its ESG Gaïa rating, achieving a score of 73/100.

The strategic collaboration between Curadh MTR Inc. and SHINE Technologies marks a pivotal moment in the advancement of cancer therapies.

AVM Biotechnology, a clinical stage company enrolling Phase 2 adaptive design/expansion cohorts for immunomodulatory AVM0703 in relapsed/refractory Non-Hodgkin Lymphoma/Leukemia patients, will present at the Bio Investor Forum, held in San Francisco, CA October 17-18, 2023.

Norgine is pleased to announce the appointment of Saulo Martiniano as its new Chief Operating Officer.

HOYA Group, PENTAX Medical announced an agreement with IRCAD, the international advanced research and training center in minimally invasive surgery based in Strasbourg, France to collaborate in education for physicians to learn advanced flexible endoscopy.

Sinovac Biotech Ltd. announced that the Company has completed the phase I clinical trial for its broad-spectrum neutralizing antibody product, the Anti-COVID-19 Antibody SA55 Injection in Beijing and has entered the phase II clinical trial in Shanghai after successfully enrolling its first participant recently.

ImmunityBio, Inc. announced that it has executed financing transactions resulting in approximately $200 million of proceeds to the Company through a financing including an exchange into equity of current debt and a new convertible debt instrument from Nant Capital, LLC, an entity affiliated with Dr. Patrick Soon-Shiong, the Company’s Founder, Executive Chairman and Global Chief Scientific and Medical Officer.

Oculis Holding AG, a global biopharmaceutical company purposefully driven to save sight and improve eye care, announced the appointment of global commercial executive with extensive ophthalmology experience, Rebecca Weil, to the role of Chief Commercial Officer.

BioLineRx Ltd. (NASDAQ/TASE: BLRX), a commercial stage biopharmaceutical company focused on certain cancers and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved APHEXDA.